
Taiho Oncology Publishes NEJM Data on First All-Oral Regimen in Newly Diagnosed AML
NEJM Publishes ASCERTAIN-V Trial Results of First All-Oral Decitabine-Cedazuridine Plus Venetoclax Regimen in AML Taiho Oncology, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for hematologic malignancies…












